American Well

Digital Health Demand Will Accelerate Converge Platform Adoption

AnalystHighTarget

Not Invested

Consensus Narrative from 6 Analysts

Published

11 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

US$12.00

40.4% undervalued

21 Aug

US$7.15

-20.7%

Author's Valuation

US$12.0

40.4% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$12.0

40.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

1.53%

Healthtech revenue growth rate

4.07%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.94%

Calculation

US$29.26m

Earnings '28

9.76x

PE Ratio '28

US$285.66m

Market Cap '28

US$285.66m

Market Cap '28

18.93m

No. shares '28

US$15.09

Share Price '28

US$15.09 Share Price '28

Discounted to 2025 @ 7.94% p.a.

US$12.00

Fair Value '25